1. Home
  2. MS vs NVS Comparison

MS vs NVS Comparison

Compare MS & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley

MS

Morgan Stanley

N/A

Current Price

$176.05

Market Cap

278.4B

Sector

Finance

ML Signal

N/A

Logo Novartis AG

NVS

Novartis AG

N/A

Current Price

$166.38

Market Cap

310.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MS
NVS
Founded
1924
1895
Country
United States
Switzerland
Employees
N/A
75267
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
278.4B
310.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MS
NVS
Price
$176.05
$166.38
Analyst Decision
Buy
Hold
Analyst Count
14
4
Target Price
$176.00
$118.00
AVG Volume (30 Days)
6.9M
2.4M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
2.30%
1.86%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$12.04
$2.65
Revenue Next Year
$5.39
$4.76
P/E Ratio
$17.30
$23.13
Revenue Growth
N/A
N/A
52 Week Low
$94.33
$97.72
52 Week High
$192.68
$168.02

Technical Indicators

Market Signals
Indicator
MS
NVS
Relative Strength Index (RSI) 48.76 67.75
Support Level $153.63 $122.16
Resistance Level $190.06 N/A
Average True Range (ATR) 5.98 1.95
MACD -0.22 0.03
Stochastic Oscillator 56.14 81.59

Price Performance

Historical Comparison
MS
NVS

About MS Morgan Stanley

Morgan Stanley is a massive global financial services firm, with offices in 42 countries and more than 82,000 employees as of year-end 2025. The firm cut its teeth in investment banking and institutional trading, where it maintains a strong presence today, but generates the lion share of its income from wealth and asset management franchises, where it boasted $9.3 trillion in client assets at the end of its most recent fiscal year. After reincorporation as a bank holding company in the wake of the global financial crisis, Morgan Stanley also boasts a top 10 banking franchise by deposits, with more than $400 billion in customer deposits, predominately attributable to cash sweeps from its wealth management and brokerage businesses.

About NVS Novartis AG

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.

Share on Social Networks: